Clinical Trial Update: Romiplostim Treatment of Thrombocytopenia in Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating romiplostim for thrombocytopenia in patients with low- or intermediate-1 risk myelodysplastic syndrome has completed with results poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes
• Thrombocytopenia

Drugs mentioned

• Romiplostim (romiplostim)

Snippet

Sponsor: Amgen | Conditions: MDS, Myelodysplastic Syndromes | Phase 2 | Status: COMPLETED | Results posted: 2013-08-13